Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Associated Therapies: -

Clinical Trials

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986195
Drug: Methotrexate
Drug: Caffeine
Drug: Montelukast
Drug: Leucovorin
Drug: Flurbiprofen
Drug: Omeprazole
Drug: Midazolam
Drug: Digoxin
Drug: Pravastatin

First Posted Date: 2017-04-27

Last Posted Date: 2017-12-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT03131973

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Decitabine
Drug: Digoxin

First Posted Date: 2017-04-13

Last Posted Date: 2021-03-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1

Registration Number: NCT03113071

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Jeans Hospital, Philadelphia, Pennsylvania, United States

TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TRK-700
Drug: Midazolam
Drug: Digoxin

First Posted Date: 2017-02-03

Last Posted Date: 2017-10-25

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 48

Registration Number: NCT03043248

Locations: 🇯🇵
Tokyo, Tokyo, Japan

Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients

Phase 1

Conditions: Head and Neck Cancer

Interventions: Drug: Digoxin

First Posted Date: 2016-09-20

Last Posted Date: 2017-10-19

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 15

Registration Number: NCT02906800

Locations: 🇫🇷
Hopital Europeen Georges Pompidou, Paris, Île-de-France, France

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Phase 1

Completed

Conditions: Influenza in Humans

Interventions: Drug: AL-794
Drug: Pitavastatin
Drug: JNJ-63623872
Drug: Digoxin
Drug: Oseltamivir
Drug: Midazolam

First Posted Date: 2016-09-05

Last Posted Date: 2018-06-25

Lead Sponsor: Alios Biopharma Inc.

Target Recruit Count: 68

Registration Number: NCT02888327

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Transporter Cocktail Mutual Interaction

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Furosemide
Drug: Metformin
Drug: Digoxin
Drug: Metformin hydrochloride
Drug: Rosuvastatin

First Posted Date: 2016-08-03

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02854527

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Digoxin
Drug: BI 425809
Drug: Warfarin
Drug: Omeprazole

First Posted Date: 2016-05-26

Last Posted Date: 2016-05-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT02783040

Locations: 🇩🇪
1346.22.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Study of SHP620 (Maribavir) in Healthy Adults

Phase 1

Completed

Conditions: Cytomegalovirus (CMV)

Interventions: Drug: Digoxin
Drug: Maribavir
Drug: Dextromethorphan

First Posted Date: 2016-05-17

Last Posted Date: 2021-06-03

Lead Sponsor: Shire

Target Recruit Count: 18

Registration Number: NCT02775240

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States

Drug Transporter Interaction Study PHENTRA_2015_KPUK

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: pitavastatin
Drug: Adefovir
Drug: digoxin
Drug: sitagliptin
Drug: Metformin

First Posted Date: 2016-04-19

Last Posted Date: 2019-09-10

Lead Sponsor: University of Cologne

Target Recruit Count: 24

Registration Number: NCT02743260

Locations: 🇩🇪
Department of Pharmacology I, University Hospital Cologne, Cologne, NRW, Germany

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Caffeine
Drug: Warfarin
Drug: Omeprazole
Drug: Midazolam
Drug: digoxin
Drug: Vitamin K
Drug: Rucaparib

First Posted Date: 2016-04-15

Last Posted Date: 2023-06-09

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 17

Registration Number: NCT02740712

Locations: 🇵🇱
BioVirtus Research Site, Kajetany, Mokra 7, Poland
🇵🇱
Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland
🇵🇱
Med Polonia, Poznan, Poland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy